Newsylist real-time news trend intelligence
▲ Peaking Health

Stronger than Ozempic. Not exactly legal. ‘Reta’ has entered the chat.

An experimental, unlicensed weight-loss drug known as 'Reta' is sparking health alarms and hospitalizations as it surfaces in unregulated markets.

5sources
5articles
3velocity
+0%since first seen
1h agofirst detected

Velocity timeline

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

3210Jul 4 01:45Jul 4 02:45 UTC

The brief

An unapproved weight-loss drug called 'Reta' is being sold through unofficial channels, including a Brooklyn bodega. Described as an experimental peptide and stronger than Ozempic, the drug is being marketed as a weight-loss quick fix.

Coverage from The Sun and AFR highlights severe health risks, linking the substance to liver damage and a wave of hospitalizations. The Sun reports that users of the unlicensed drug have turned yellow.

Other reports from CBS News and AOL.com focus on the availability of the drug in retail settings. Future developments depend on the scale of hospitalizations and the legal status of the drug's distribution, as current coverage emphasizes its unlicensed and experimental nature.

Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 56m ago.

Quick answers

What is 'Reta'?

Reta is an experimental, unlicensed weight-loss drug and peptide that is described as being stronger than Ozempic.

Where is the drug being sold?

According to AOL.com and CBS News, the drug has been sold at a Brooklyn bodega.

What are the reported side effects?

Coverage from The Sun and AFR links the drug to liver damage, users turning yellow, and a wave of hospitalizations.

Coverage (5)

People, places & organizations

Topics

Related trends